| scholarly article | Q13442814 |
| P50 | author | Ruth Manners | Q43159903 |
| Terry J. Smith | Q45933677 | ||
| Raymond S Douglas | Q51353730 | ||
| Hélène Chokron Garneau | Q70952179 | ||
| P2093 | author name string | Mark Gordon | |
| Dinesh Khanna | |||
| Jimmy Uddin | |||
| Robert A Goldberg | |||
| Diana Lee | |||
| Michael Kazim | |||
| Peter J Dolman | |||
| Angelo Tsirbas | |||
| Victor Elner | |||
| Mark Lucarelli | |||
| Nicole Khadavi | |||
| Kenneth Cahill | |||
| Steve Feldon | |||
| International Thyroid Eye Disease Society | |||
| P2860 | cites work | New insights into pathogenesis and potential therapeutic options for Graves orbitopathy | Q33808859 |
| Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. | Q34010116 | ||
| Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. | Q34065922 | ||
| A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes | Q34421851 | ||
| International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis | Q34536278 | ||
| Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs | Q34546789 | ||
| EULAR evidence-based recommendations for the management of fibromyalgia syndrome | Q34654765 | ||
| Ankylosing spondylitis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs--results of a consensus development (Delphi) exercise | Q34688716 | ||
| Rheumatoid arthritis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs--results of a consensus development (Delphi) exercise | Q34704980 | ||
| Graves' ophthalmopathy: a rational approach to treatment | Q34774478 | ||
| The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice | Q35163376 | ||
| Assessing quality of life in Australian patients with Graves' ophthalmopathy | Q35591594 | ||
| First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis | Q35636900 | ||
| Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study | Q35638054 | ||
| Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis | Q35842626 | ||
| Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey | Q36014781 | ||
| Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel | Q36033045 | ||
| Modulation of TNF receptor family members to inhibit autoimmune disease | Q36107640 | ||
| Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort | Q36171802 | ||
| Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers | Q36568033 | ||
| Pharmacological treatments for thyroid eye disease. | Q36595134 | ||
| VISA Classification for Graves orbitopathy | Q36598248 | ||
| ACR remission criteria and response criteria | Q36644059 | ||
| EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis | Q36684589 | ||
| Systemic sclerosis - continuing progress in developing clinical measures of response. | Q36810200 | ||
| A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index | Q36869412 | ||
| Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy | Q37110191 | ||
| Novel immunomodulating agents for Graves orbitopathy. | Q37223404 | ||
| Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease | Q39233800 | ||
| Outcome measurements in scleroderma: results from a delphi exercise | Q40242398 | ||
| Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. | Q40425699 | ||
| Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach | Q40498818 | ||
| Clever Is Not Enough: NOSPECS Is Form in Search of Function | Q44437235 | ||
| Commentary: selecting performance measures by consensus: an appropriate extension of the delphi method? | Q45965939 | ||
| The reproducibility of a method to identify the overuse and underuse of medical procedures | Q46145870 | ||
| Scleroderma--developing measures of response | Q46185102 | ||
| Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience | Q47945181 | ||
| Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. | Q50933902 | ||
| Psychosocial factors in subjects with thyroid-associated ophthalmopathy. | Q51958009 | ||
| Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. | Q53224753 | ||
| Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis | Q57824216 | ||
| Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study | Q79546631 | ||
| B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study | Q79734838 | ||
| Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort | Q80062133 | ||
| Transitional care for adolescents with juvenile idiopathic arthritis: a Delphi study | Q80102944 | ||
| Disease-specific assessment of quality of life after decompression surgery for Graves' ophthalmopathy | Q80219928 | ||
| The EUGOGO consensus statement on the management of Graves' orbitopathy: equally applicable to North American clinicians and patients | Q80873629 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 1155-1160 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | JAMA Ophthalmology | Q4787301 |
| P1476 | title | Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique | |
| P478 | volume | 127 |
| Q38689548 | "The patient is speaking": discovering the patient voice in ophthalmology |
| Q40096041 | Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases |
| Q37772737 | Pathogenesis of Graves' orbitopathy: a 2010 update. |
| Q92381046 | Prognostic factors for TB-associated uveitis in the Asia-Pacific Region: results of a modified Delphi survey |
| Q33741009 | Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab |
| Q37987063 | Thyroid eye disease: towards an evidence base for treatment in the 21st century |
| Q42925094 | Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression |
| Q38924690 | What are the priorities for improving cataract surgical outcomes in Africa? Results of a Delphi exercise. |
| Q55059772 | Which outcomes are most important to people with aphasia and their families? an international nominal group technique study framed within the ICF. |
Search more.